Loading...
Loading...
NRBO| Name | Value |
|---|---|
| Revenues | 0.0K |
| Cost of Revenue | 0.0K |
| Gross Profit | 0.0K |
| Operating Expense | 2,220.0K |
| Operating I/L | -10,430.0K |
| Other Income/Expense | 5,754.0K |
| Interest Income | 0.0K |
| Pretax | -4,676.0K |
| Income Tax Expense | -5,670.0K |
| Net Income/Loss | 994.0K |
NeuroBo Pharmaceuticals, Inc. is a clinical-stage biotechnology company specializing in therapies for neurodegenerative, infectious, and cardiometabolic diseases. The company's key therapeutic programs include ANA001, an oral niclosamide formulation in Phase 2/3 clinical trials for moderate COVID-19, NB-01 for painful diabetic neuropathy, NB-02 for cognitive impairment and neurodegenerative diseases associated with tau protein malfunction, and Gemcabene for acute COVID-19 indications.
